Severe Hypocalcemia due to Denosumab in Metastatic Prostate Cancer

Hypocalcemia is a rare and dangerous side effect of the drug Denosumab. We will introduce metastatic prostate cancer patients who developed severe hypocalcemia after administration. A total of 80 grams of intravenous calcium and 370 grams of oral calcium were administered intravenously and the maximum ionized calcium level achieved during the first 16 days of hospitalization was 0.71 mmol / l. Because of the deterioration of renal failure caused by tumor spread, our patients require dialysis to reach normal calcium levels.

Men with prostate cancer may be explained as having a low risk of developing / developing a metastatic disease or dying of prostate cancer, stroke or high risk. PSA level is one of the three variables underlying risk stratification, the others are stage of cancer based on prostate cancer grade (Gleason grading system) and physical examination and imaging examination. The D'Amico standards of each risk category are as follows. Taking into account the relative simplicity of the 1998 D'Amico standard (above), there are other predictive models of risk stratification based on mathematical probabilistic structures. Matching therapy makes decisions about the characteristics of the disease. Ongoing studies involving multiparametric MRI imaging result in nomograms depending on PSA, Gleason grading, and tumor staging

Hypocalcemia is a rare and dangerous side effect of the drug Denosumab. We will introduce metastatic prostate cancer patients who developed severe hypocalcemia after administration. A total of 80 grams of intravenous calcium and 370 grams of oral calcium were administered intravenously and the maximum ionized calcium level achieved during the first 16 days of hospitalization was 0.71 mmol / l. Because of the deterioration of renal failure caused by tumor spread, our patients require dialysis to reach normal calcium levels.

There are several treatment options available for PCa management. Low risk prostate cancer is managed through aggressive monitoring to prevent unwanted radiation and surgical exposure. Treatment of moderate or high risk non-metastatic prostate cancer by prostatectomy or radiotherapy (Zietman et al., 2010). Invasive and metastatic prostate cancer is treated with total prostatectomy (RP), radiation therapy (RT), chemotherapy, cryosurgery, hormone therapy (HT), and bisphosphonate. These combination therapy options correspond to the trend of invasive PCa metastasis to adjacent structures / organs